Active neutrality policy of Republic of Turkey during World War Two and the Foreign Ministry of Numan Menemencioglu
2020
0 views
0 downloads
Advisor: Dr. Furkan Kaya
Abstract (EN)
In this postgraduate thesis, active neutrality policy of Republic of Turkey and the foreign ministry period of Numan Menemencioglu will be told. In order to understand the situation of Republic of Turkey during World War 2, diplomacy among other nations who entered the World War 2 will be examined. Also, the reasons for World War 2 and the interwar period will be mentioned. Origins of World War 2 will help us to understand the developments of World War 2 efficiently. The most important diplomatic figures of Republic of Turkey during World War 2 will be told. Active neutrality policy will be told in regard to the diplomatic and economic incidents during World War 2. The relations between Republic of Turkey and warring states will be analyzed, how Republic of Turkey remained non-combatant during the period will be focused. Keywords: active neutrality, World War 2, Menemencioglu, Inonu, Turkey, foreign policy
Author
Fatih Albayrak
How to Cite
Fatih Albayrak (Master Thesis). Active neutrality policy of Republic of Turkey during World War Two and the Foreign Ministry of Numan Menemencioglu, 2020, Yeditepe University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)